Skip to Main Content

Author Details

Shuai Gao
Center for Personalized Cancer Therapy, University of Massachusetts Boston
2012
31
15
PMIDPaper TitleJournal TitlePublished Year
36877164LSD1 Inhibition Disrupts Super-Enhancer-Driven Oncogenic Transcriptional Programs in Castration-Resistant Prostate Cancer.Cancer Res2023
37663929Demethylation of EHMT1/GLP Protein Reprograms Its Transcriptional Activity and Promotes Prostate Cancer Progression.Cancer Res Commun2023
37549269SETD7 functions as a transcription repressor in prostate cancer via methylating FOXA1.Proc Natl Acad Sci U S A2023
35031563Inhibition of EZH2 transactivation function sensitizes solid tumors to genotoxic stress.Proc Natl Acad Sci U S A2022
36408179Increased <i>AR</i> expression in castration-resistant prostate cancer rapidly induces AR signaling reprogramming with the collaboration of EZH2.Front Oncol2022
34975152RB1 loss in castration-resistant prostate cancer confers vulnerability to LSD1 inhibition.Oncogene2022
35121110Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancer.Mol Ther2022
33632899Susceptibility-Associated Genetic Variation in <i>NEDD9</i> Contributes to Prostate Cancer Initiation and Progression.Cancer Res2021
32146024Attitude of Students in Shanghai University of Traditional Chinese Medicine Toward Donation After Cardiac Death.Transplant Proc2020
32868907Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer.Nat Genet2020
30718921TMPRSS2-ERG activates NO-cGMP signaling in prostate cancer cells.Oncogene2019
31324883Forkhead domain mutations in FOXA1 drive prostate cancer progression.Cell Res2019
31428587LSD1 Activates PI3K/AKT Signaling Through Regulating p85 Expression in Prostate Cancer Cells.Front Oncol2019
31444154ZBTB7A Mediates the Transcriptional Repression Activity of the Androgen Receptor in Prostate Cancer.Cancer Res2019
29059155Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer.Oncogene2018
28036278A novel nonsense mutation in androgen receptor confers resistance to CYP17 inhibitor treatment in prostate cancer.Oncotarget2017
28465296Exploiting AR-Regulated Drug Transport to Induce Sensitivity to the Survivin Inhibitor YM155.Mol Cancer Res2017
28916652LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression.Cancer Res2017
28859127Peptide B targets soluble guanylyl cyclase α1 and kills prostate cancer cells.PLoS One2017
27081086Effect of CTLA-4 gene polymorphisms on long-term kidney allograft function in Han Chinese recipients.Oncotarget2016
27760327Androgen Receptor Tumor Suppressor Function Is Mediated by Recruitment of Retinoblastoma Protein.Cell Rep2016
27524236Molecular mechanisms of synergistic induction of apoptosis by the combination therapy with hyperthermia and cisplatin in prostate cancer cells.Biochem Biophys Res Commun2016
26936914ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer.Clin Cancer Res2016
25320358Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors.Clin Cancer Res2015
26444683Time Course of Cell Sheet Adhesion to Porcine Heart Tissue after Transplantation.PLoS One2015
25808865PLZF, a tumor suppressor genetically lost in metastatic castration-resistant prostate cancer, is a mediator of resistance to androgen deprivation therapy.Cancer Res2015
24874833Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor.Clin Cancer Res2014
25482560Lysine-specific demethylase 1 has dual functions as a major regulator of androgen receptor transcriptional activity.Cell Rep2014
23724033A peptide against soluble guanylyl cyclase α1: a new approach to treating prostate cancer.PLoS One2013
24236047Zinc Finger 280B regulates sGCα1 and p53 in prostate cancer cells.PLoS One2013
22174378Soluble guanylyl cyclase α1 and p53 cytoplasmic sequestration and down-regulation in prostate cancer.Mol Endocrinol2012
  • 1 - 31 of 31

Recommended Authors

Yuliang Wang
The Chinese University of Hong Kong
Career Start Year 2014
Number of shared co-authors 0
Xinpei Ci
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2013
Number of shared co-authors 14
Alec Paschalis
The Institute for Cancer Research
Career Start Year 2009
Number of shared co-authors 1
Alfonso Urbanucci
Northwestern University Feinberg School of Medicine Chicago
Career Start Year 2008
Number of shared co-authors 10
Anne Haegert
University of British Columbia
Career Start Year 2008
Number of shared co-authors 10
Alastair Davies
University of British Columbia
Career Start Year 2008
Number of shared co-authors 9
Yu Chen
School of Pharmacy, University of Wisconsin-Madison
Career Start Year 2008
Number of shared co-authors 12
Leigh Ellis
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Career Start Year 2007
Number of shared co-authors 23
Hui Xue
Agricultural Genomics Institute at Shenzhen, Chinese Academy of Agricultural Sciences
Career Start Year 2005
Number of shared co-authors 19
Michael C Haffner
Fred Hutchinson Cancer Center
Career Start Year 2005
Number of shared co-authors 21
Alok K Tewari
Dana-Farber Cancer Institute, Harvard Medical School
Career Start Year 2005
Number of shared co-authors 5
Charlie E Massie
University of Cambridge
Career Start Year 2003
Number of shared co-authors 2
Adam Sharp
The Institute for Cancer Research
Career Start Year 2003
Number of shared co-authors 17
Ladan Fazli
University of British Columbia
Career Start Year 2002
Number of shared co-authors 23
Luke A Selth
Adelaide Medical School, University of Adelaide
Career Start Year 2002
Number of shared co-authors 10
Sooryanarayana Varambally
University of Alabama at Birmingham, USA O'Neal Comprehensive Cancer Center
Career Start Year 2001
Number of shared co-authors 4
Jiaoti Huang
Duke University School of Medicine
Career Start Year 2000
Number of shared co-authors 14
Nadia Boufaied
Research Institute of the McGill University Health Centre
Career Start Year 2000
Number of shared co-authors 12
Yuzhuo Wang
University of British Columbia
Career Start Year 2000
Number of shared co-authors 22
Kristiina Iljin
VTT Technical Research Centre of Finland Ltd
Career Start Year 1999
Number of shared co-authors 0
Srinivasan Yegnasubramanian
Johns Hopkins University School of Medicine
Career Start Year 1999
Number of shared co-authors 8
Joshi J Alumkal
Rogel Cancer Center, University of Michigan ann arbor
Career Start Year 1999
Number of shared co-authors 15
Xuhong Cao
Michigan Center for Translational Pathology.
Career Start Year 1999
Number of shared co-authors 14
Ian G Mills
Queen's University Belfast
Career Start Year 1997
Number of shared co-authors 12
Nupam P Mahajan
Washington University in St Louis
Career Start Year 1996
Number of shared co-authors 6
Arul M Chinnaiyan
University of Michigan Medical School.
Career Start Year 1993
Number of shared co-authors 22
Guido Jenster
Erasmus University Medical Center
Career Start Year 1990
Number of shared co-authors 11
Gyorgy Petrovics
Henry Jackson Foundation for the Advancement of Military Medicine (HJF)
Career Start Year 1990
Number of shared co-authors 7
Martin E Gleave
University of British Columbia
Career Start Year 1987
Number of shared co-authors 28
Tapio Visakorpi
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year 1987
Number of shared co-authors 10

Collaborators

Changmeng Cai
Center for Personalized Cancer Therapy, University of Massachusetts Boston
Co-authored papers 24
Wanting Han
Center for Personalized Cancer Therapy, University of Massachusetts Boston
Co-authored papers 14
Housheng Hansen He
Princess Margaret Cancer Center, University Health Network, University of Toronto
Co-authored papers 13
Steven P Balk
Beth Israel Deaconess Medical Center and Harvard Medical School
Co-authored papers 12
Musaddeque Ahmed
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 5
Sujun Chen
Princess Margaret Cancer Center/University Health Network
Co-authored papers 5
Eva Corey
University of Washington School of Medicine
Co-authored papers 4
Peter S Nelson
Fred Hutchinson Cancer Center
Co-authored papers 4
Myles Brown
Co-authored papers 3
Yan Gao
Co-authored papers 3
Philip W Kantoff
Memorial Sloan Kettering Cancer Center
Co-authored papers 3
Elahe A Mostaghel
University of Washington
Co-authored papers 2
Cheryl H Arrowsmith
University of Toronto
Co-authored papers 2
Mary-Ellen Taplin
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
Co-authored papers 2
Huihui Ye
College of Optical Science and Engineering, Zhejiang University
Co-authored papers 2
Xiaole Shirley Liu
Co-authored papers 2
Adam G Sowalsky
National Cancer Institute
Co-authored papers 2
Yi Liang
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 2
Haiyang Guo
the Second Hospital, Cheeloo College of Medicine, Shandong University
Co-authored papers 1
Wei Li
Co-authored papers 1
Alexandra Corella
Fred Hutchinson Cancer Research Center
Co-authored papers 1
Timothy R Rebbeck
Center for Cancer Equity and Engagement, Dana-Farber/Harvard Cancer Center
Co-authored papers 1
Brian Li
Mid & South Essex NHS Foundation Trust
Co-authored papers 1
Amina Zoubeidi
University of British Columbia
Co-authored papers 1
James E Bradner
Co-authored papers 1
Massimo Loda
Weill Medical College of Cornell University
Co-authored papers 1
Muhammad B Ekram
Louisiana State University
Co-authored papers 1
Eliezer M Van Allen
Dana-Farber Cancer Institute
Co-authored papers 1
Paul C Boutros
University of California los angeles
Co-authored papers 1
Anthony M Joshua
The Kinghorn Cancer Centre, St. Vincent's Hospital Sydney
Co-authored papers 1
Release 1.2